Skip Navigation


Annals of Oncology Advance Access originally published online on September 15, 2006
Annals of Oncology 2006 17(11):1673-1676; doi:10.1093/annonc/mdl287
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
17/11/1673    most recent
mdl287v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Berghmans, T
Right arrow Articles by Sculier, J-P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berghmans, T
Right arrow Articles by Sculier, J-P
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

lung cancer

Thyroid transcription factor 1—a new prognostic factor in lung cancer: a meta-analysis

T Berghmans1,*, M Paesmans2, C Mascaux1, B Martin1, A-P Meert1, A Haller3, J-J Lafitte4 and J-P Sculier1

1 Department of Intensive Care and Thoracic Oncology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium
2 Data Centre, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium
3 Department of Pathology, Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles, Belgium
4 Chest Department, Centre Hospitalier Universitaire Calmette, Lille, France

*Correspondence to: Dr T. Berghmans, Institut Jules Bordet, rue Héger-Bordet, 1, B-1000 Brussels, Belgium. Tel: +32-2-541-31-91; Fax: +32-2-534-37-56; E-mail: thierry.berghmans{at}bordet.be

Background: The aim of this study was to determine the prognostic role for survival of thyroid transcription factor 1 (TTF-1) in lung cancer.

Methods: Studies evaluating survival and TTF-1 in lung cancer patients, published until August 2005, were assessed with a methodological scoring system. The required data for estimation of individual hazard ratios (HRs) for survival were extracted from the publications and a combined HR was calculated.

Results: We identified 10 eligible papers, all dealing with non-small-cell lung cancer (NSCLC). Eight were meta-analysed (evaluable studies). Seven studies included patients with local and/or locoregional diseases and three dealt only with adenocarcinoma. Median methodological quality score was 65.9% (range = 31.8%–70.5%). TTF-1 positivity was associated with statistically significant reduced or improved survival in one and four studies, respectively. Combined HR for the eight evaluable studies was 0.64 [95% confidence interval (CI) = 0.41–1.00]. In the subgroup of adenocarcinoma, the combined HR was 0.53 (95% CI = 0.29–0.95).

Conclusion: TTF-1 is a good prognostic factor for survival in NSCLC. Its effect appears also significant when the analysis is restricted to patients with adenocarcinoma. This study supports the fact that TTF-1 could be included in further prospective trials studying prognostic factors in NSCLC.

Key words: lung cancer, meta-analysis, prognostic factor, survival, systematic review, thyroid transcription factor 1


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.